We are a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Our proprietary Tailored Covalency® platform enables us to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities that we believe will rival those of injectable biologics, yet maintain the convenience of a pill. Our strategy is to advance the development of our proprietary drug candidates, and for certain programs, use collaborations and partnerships as strategic tools to maximize the value of those assets.
Powered by Tailored Covalency®
Principia Biopharma challenges traditional drug discovery by utilizing its proprietary technology to discover new medicines that combine the dosing convenience of an oral small molecule drug with the specificity of an antibody.
Principia’s leadership team includes biotechnology executives and veteran drug developers who are passionate about creating a new way to develop better small molecule drugs.
Board of Directors